Quick Answer
Vicapsys Life Sciences, Inc. reported Operating Income of -$1.05 million for fiscal year 2023.
Vicapsys Life Sciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2023 | -$1.05M | -6.3% |
| 2022 | -$984.8K | -192.3% |
| 2021 | -$336.9K | +56.0% |
| 2020 | -$765.8K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$198.9K | -13.4% | -9.4% |
| June 30, 2024 | -$181.8K | -34.0% | +11.0% |
| March 31, 2024 | -$204.3K | +3.3% | -16.4% |
| September 30, 2023 | -$175.4K | -20.9% | -29.3% |
| June 30, 2023 | -$135.7K | +24.6% | +35.8% |
| March 31, 2023 | -$211.3K | -26.5% | -45.6% |
| September 30, 2022 | -$145.1K | -30.5% | +19.4% |
| June 30, 2022 | -$180.1K | -149.9% | -7.8% |
- Vicapsys Life Sciences, Inc. showed a decrease of -6.3% in Operating Income compared to the prior fiscal year.
- Over the 2020–2023 period, Vicapsys Life Sciences, Inc.’s operating income has declined by 36.7% (from -$765.8 thousand to -$1.05 million).
- The most recent figure is from Vicapsys Life Sciences, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on October 21, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: